Uncategorized

EnLiSense CCM Advances Validation of Real-Time IBD Inflammatory Biomarker Monitoring with Two Recent Peer-Reviewed Longitudinal Studies

EnLiSense CCM, a pioneer in non-invasive sweat-sensor technology for real-time health monitoring, is thrilled to announce a groundbreaking advancement in the world of Inflammatory Bowel Disease management.

EnLiSense CCM Advances Validation of Real-Time IBD Inflammatory Biomarker Monitoring with Two Recent Peer-Reviewed Longitudinal Studies Read More »

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced that its Chairman and Chief Executive Officer, Lishan Aklog, M.D., highlighted Lucid’s EsoCheck® Cell Collection Device during testimony before the U.S. House of Representatives’ Committee on Small Business.

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony Read More »

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis

Pharus Diagnostics announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma.

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis Read More »

Scroll to Top